Extended Data Fig. 2: EDGE-Gastric study design. | Nature Medicine

Extended Data Fig. 2: EDGE-Gastric study design.

From: Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial

Extended Data Fig. 2

1 L, first line; 2 L, second line; CPI, checkpoint inhibitor; FOLFOX, oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, fluorouracil 400 mg/m2 on day 1 and fluorouracil 2400 mg/m2 on days 1 and 2 (continuous 46–48-hour infusion); IV, intravenous; min, minute; Q2W, once every 2 weeks; Q3W, once every 3 weeks; Q4W, once every 4 weeks; R, randomized.

Back to article page